Check here to see clinical cancer trials that are currently enrolling patients.

Below you will see clinical cancer trials in Eastern Finland.

Cancer trials

ONCOLOGY

TALAPRO-2 (Kuopio)

NCT03395197

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

RECRUITING

To get more information contact:

Okko Kääriäinen
okko.kaariainen@kuh.fi
044-7179433

Updated 25 August 2020.

 

KuPSMALu-177 (Kuopio)

RECRUITING STARTS ON AUTUMN 2020

To get more information contact:

Okko Kääriäinen
okko.kaariainen@kuh.fi
044-7179433

Updated 25 August 2020.

 

LCBIOMARKERS (Kuopio)

RECRUITING

To get more information contact:

Okko Kääriäinen
okko.kaariainen@kuh.fi
044-7179433

Updated 25 August 2020.

 

BIO-CHIC (Kuopio and Jyväskylä)

NCT03293173

This study is testing whether stratification of the patients according to biological risk factors for different treatment groups will improve the outcome of patients with clinically high diffuse large B-cell lymphoma (DLBCL).

RECRUITING

To get more information contact:

Okko Kääriäinen
okko.kaariainen@kuh.fi
044-7179433

Updated 25 August 2020.

 

POLARBEAR (Kuopio)

NCT04332822

This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy and Switzerland, in elderly patients with untreated diffuse large B-cell lymphoma.

 

RECRUITING

To get more information contact:

Okko Kääriäinen
okko.kaariainen@kuh.fi
044-7179433

Updated 25 August 2020.

 

MK6482-005 (Kuopio)

 

RECRUITING

To get more information contact:

Okko Kääriäinen
okko.kaariainen@kuh.fi
044-7179433

Updated 25 August 2020.

 

CA045-001 (Kuopio)

 

RECRUITING STARTS ON AUTUMN 2020

To get more information contact:

Okko Kääriäinen
okko.kaariainen@kuh.fi
044-7179433

Updated 25 August 2020.

 

IOPredict (Kuopio)

 

RECRUITING

To get more information contact:

Okko Kääriäinen
okko.kaariainen@kuh.fi
044-7179433

Updated 25 August 2020.

 

COVID and Cancer (Kuopio)

Research about how COVID affects to cancer patients.

RECRUITING

To get more information contact:

Okko Kääriäinen
okko.kaariainen@kuh.fi
044-7179433

Updated 25 August 2020.

MK3475-991 / KEYNOTE-991 (Jyväskylä)

NCT04191096

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT in participants with mHSPC.

RECRUITING

To get more information contact:

Heikki Hakkarainen
heikki.hakkarainen@kuh.fi

Updated 23 October 2020.

LYMRIT-37-01 (Jyväskylä)

NCT01796171

This study is a phase I/II, open-label study in patients with relapsed indolent non-Hodgkin lymphoma. Part A of the study included a phase I dose escalation to define the maximum tolerated / recommended dose for expansion of (177Lu)-lilotomab (Betalutin), and a phase IIa part to evaluate safety and preliminary efficacy. Part B of the study will assess the efficacy and safety of two different Betalutin/lilotomab dosing regimens in adult patients with relapsed rituximab / anti-CD20-refractory follicular lymphoma who have received 2 or more prior therapies.

RECRUITING

To get more information contact:

Heikki Hakkarainen
heikki.hakkarainen@kuh.fi

Updated 23 October 2020.